Eventide Healthcare & Life Sciences A
ETAHX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Willow Grove, PA19090 OH United States of America
- IPO Date
- Dec 27, 2012
- CIK
- 0001355064
- Website
- eventideinvestments.com
- Similar Companies
- Business
- Eventide Healthcare & Life Sciences Fund (ETAHX) is a diversified open-end mutual fund that seeks long-term capital appreciation by investing at least 80% of its net assets in equity securities and equity-related instruments of companies in the healthcare and life sciences sectors, with a concentration of at least 25% in drug-related industries; the fund also allocates up to 15% to illiquid securities, including private investments, IPOs, and mezzanine financing offerings. It focuses on early development-stage companies with median market capitalizations of $2.4 billion, targeting firms addressing large unmet medical needs such as rare and orphan diseases, pulmonary infections, pediatric cholestasis, cancer diagnostics, neuromuscular disorders, autoimmune conditions, and neurological disorders through innovative therapeutics, diagnostics, devices, and services; top holdings as of late 2025 include Insmed Inc., Mirum Pharmaceuticals Inc., Guardant Health Inc., Celcuity Inc., and Scholar Rock. The fund, domiciled in the United States and available primarily to U.S. investors, maintains a portfolio of approximately 71 holdings across biotechnology, pharmaceuticals, healthcare services, and healthcare technology, with total net assets exceeding $1.6 billion as of December 2025. Launched on December 27, 2012, and managed by Eventide Asset Management LLC, headquartered at One International Place, Suite 4210, Boston, Massachusetts, the fund operates within the Morningstar US Fund Health category under a small-cap growth investment style. Lead portfolio manager Finny Kuruvilla, MD, PhD, Co-Chief Investment Officer, Senior Portfolio Manager, and Founding Member of Eventide (established 2008), oversees the strategy alongside Co-Portfolio Manager I-hung Shih, PhD, who joined in September 2024 as Managing Director of Eventide Ventures after serving as Co-Head of Biotech Private Investments at Wellington Management. Recent developments include the hiring of I-hung Shih, PhD, in August 2024 to enhance biotech expertise and co-manage the fund, as well as Eventide's successful final close in May 2024 of its inaugural dedicated private investment vehicle, the Eventide Healthcare Innovation Fund I, LP, raising $83 million from endowments, foundations, and family offices to invest in private biotech firms nearing value-creation milestones in therapeutics, devices, and diagnostics—building on Eventide's prior deployment of over $500 million across 38 private healthcare companies. These strategic enhancements align with Eventide Ventures' expansion into private markets while maintaining the fund's emphasis on high-conviction public and private healthcare equities for ethical, sustainable growth.